全文获取类型
收费全文 | 11668篇 |
免费 | 1112篇 |
出版年
2023年 | 57篇 |
2022年 | 86篇 |
2021年 | 288篇 |
2020年 | 180篇 |
2019年 | 221篇 |
2018年 | 249篇 |
2017年 | 204篇 |
2016年 | 328篇 |
2015年 | 524篇 |
2014年 | 639篇 |
2013年 | 613篇 |
2012年 | 841篇 |
2011年 | 847篇 |
2010年 | 490篇 |
2009年 | 425篇 |
2008年 | 591篇 |
2007年 | 547篇 |
2006年 | 528篇 |
2005年 | 427篇 |
2004年 | 395篇 |
2003年 | 370篇 |
2002年 | 308篇 |
2001年 | 219篇 |
2000年 | 223篇 |
1999年 | 187篇 |
1998年 | 95篇 |
1997年 | 95篇 |
1996年 | 78篇 |
1994年 | 67篇 |
1993年 | 76篇 |
1992年 | 139篇 |
1991年 | 137篇 |
1990年 | 128篇 |
1989年 | 133篇 |
1988年 | 103篇 |
1987年 | 111篇 |
1986年 | 109篇 |
1985年 | 138篇 |
1984年 | 127篇 |
1983年 | 117篇 |
1982年 | 92篇 |
1981年 | 74篇 |
1980年 | 89篇 |
1979年 | 119篇 |
1978年 | 73篇 |
1977年 | 69篇 |
1976年 | 67篇 |
1975年 | 72篇 |
1974年 | 85篇 |
1972年 | 62篇 |
排序方式: 共有10000条查询结果,搜索用时 429 毫秒
21.
Gregory Plunkett Donald F. Senear Glen Zuroske Clarence A. Ryan 《Archives of biochemistry and biophysics》1982,219(2):463-464
Proteinase inhibitors I and II were purified to electrophoretic homogeneity from leaves of tomato plants induced by either wounding intact plants or by supplying excised plants with the proteinase inhibitor inducing factor. Affinity chromatography with chymotrypsin-Sepharose was employed as a final purification step for each inhibitor. The tomato leaf inhibitors are very similar to potato tuber inhibitors I and II in subunit molecular weight, composition, and inhibitory activities against chymotrypsin, trypsin, and subtilisin. However, unlike the potato tuber which contains multiple isoinhibitors by isoelectric focusing, the tomato leaf exhibits only two isoinhibitor forms of inhibitor I and a single form of inhibitor II. The molecular weight of native potato inhibitor I was reevaluated by rigorous ultracentrifugal analysis and compared with data from previous analyses. The data confirm that native inhibitor I has a native Mr of about 41,000 and is a pentamer. Inhibitor II has a molecular weight of near 23,000 and is a dimer. 相似文献
22.
Terence Kennedy 《BMJ (Clinical research ed.)》1968,4(5628):450-451
23.
24.
25.
26.
27.
Auditory cues can create the illusion of self-motion (vection) in the absence of visual or physical stimulation. The present study aimed to determine whether auditory cues alone can also elicit motion sickness and how auditory cues contribute to motion sickness when added to visual motion stimuli. Twenty participants were seated in front of a curved projection display and were exposed to a virtual scene that constantly rotated around the participant''s vertical axis. The virtual scene contained either visual-only, auditory-only, or a combination of corresponding visual and auditory cues. All participants performed all three conditions in a counterbalanced order. Participants tilted their heads alternately towards the right or left shoulder in all conditions during stimulus exposure in order to create pseudo-Coriolis effects and to maximize the likelihood for motion sickness. Measurements of motion sickness (onset, severity), vection (latency, strength, duration), and postural steadiness (center of pressure) were recorded. Results showed that adding auditory cues to the visual stimuli did not, on average, affect motion sickness and postural steadiness, but it did reduce vection onset times and increased vection strength compared to pure visual or pure auditory stimulation. Eighteen of the 20 participants reported at least slight motion sickness in the two conditions including visual stimuli. More interestingly, six participants also reported slight motion sickness during pure auditory stimulation and two of the six participants stopped the pure auditory test session due to motion sickness. The present study is the first to demonstrate that motion sickness may be caused by pure auditory stimulation, which we refer to as “auditorily induced motion sickness”. 相似文献
28.
29.
30.
The Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial is a multicentre,randomised, placebo-controlled trial of magnesium sulphate (MgSO4) funded by the UK Medical Research Council. When complete, it will be the largest single neuroprotective study undertaken to date. Conscious patients presenting within 12 h of acute stroke with limb weakness are eligible. The primary outcome measure is combined death and disability as measured using the Barthel Index at 90-day follow up. By randomizing 2700 patients, the study will have 84% power to detect a 5.5% absolute reduction in the primary end-point. By April 2000, 86 centres were participating, with representation in Canada, USA, Europe, South America, Singapore and Australia. So far, 1206 patients have been randomised, of whom 37% were treated within 6 h. Overall 3-month mortality was 20% and the primary outcome event rate was 43%. The study is ongoing and centres worldwide are encouraged to participate. 相似文献